coronary News

To earn the award, South Nassau needed to adhere to the treatment guidelines in ACTION Registry–GWTG for 12 consecutive quarters (three years) and meet a performance standard of at least 85% for specific performance measures.

The rapid discovery of treatments for vascular diseases demands rapid development of device initiatives.

New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

Netscribes (India) Pvt. Ltd., launches its ECG Equipment Market in India 2011report covering one of the emerging markets in India with strong growth prospects . It is a part of Netscribes’ Healthcare Series reports.

Gamma Therapeutics, an Oregon biotech venture announced its been awarded a Phase II SBIR grant from the NIH to commercialize its GammaCoeur CVD Risk Assay. The $1.1 M grant allows GT to complete development, testing & final FDA approval by 2012.

New Pharmaceuticals market report from GlobalData: "Coronary Artery Disease (CAD) Global Clinical Trials Review, Q1, 2011"

Breakthrough medical tests helping to combat heart disease

Recently published research from GlobalData, "Interventional Cardiology Devices Global Market Briefing to 2016", is now available at Fast Market Research

South Nassau Communities Hospital has been awarded a Gold Performance Achievement Award in Coronary Artery Disease from the American Heart Association/American Stroke Association's Get with the Guidelines program.

Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

Aarkstore announce a new report "Stakeholder Insight: Percutaneous Coronary Intervention – A comparison between US and EU practice" through its vast collection of market reserach report.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.

Vancouver, Canada, June 19th, 2009 - Symbiorph Biomedical Corporation is pleased to announce that it has received CE mark approval for the enhancement in profile and size range of its SYMTREK™ rapid exchange coronary dilatation catheter.

Treatment of coronary artery disease has become a hotbed for evaluation of an incredible range of alternatives, but drug-eluting stents (DES) clearly represent the most attractive option, according to a new report from MedMarket Diligence (MMD).

Coronary artery disease is addressed by a range alternative treatment methodologies; percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other options, but stents represent the fastest growing option.